Regorafenib,Nivolumab,Docetaxel,Paclitaxel,Irinotecan,trifluridine tipiracil
Bayer,BMS,Taiho pharma
[]
rogerafenib for 3rd line for stomach cancer . integrate phase iia trial 19 % survival at the end of 12 moths . hr for os 0.68 . phase3 trial may give more information #asco23 #gi23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists